vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与CSW INDUSTRIALS, INC.（CSW）财务数据对比。点击上方公司名可切换其他公司
CSW INDUSTRIALS, INC.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.5倍（$233.0M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 4.4%，领先30.1%），CSW INDUSTRIALS, INC.同比增速更快（20.3% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $22.7M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 5.1%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
CPRX vs CSW — 直观对比
营收规模更大
CSW
是对方的1.5倍
$152.6M
营收增速更快
CSW
高出12.7%
7.6%
净利率更高
CPRX
高出30.1%
4.4%
自由现金流更多
CPRX
多$22.1M
$22.7M
两年增速更快
CPRX
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $233.0M |
| 净利润 | $52.7M | $10.3M |
| 毛利率 | 82.9% | 39.7% |
| 营业利润率 | 40.5% | 7.4% |
| 净利率 | 34.5% | 4.4% |
| 营收同比 | 7.6% | 20.3% |
| 净利润同比 | -5.8% | -61.9% |
| 每股收益（稀释后） | $0.40 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXCSW
| Q4 25 | $152.6M | $233.0M | ||
| Q3 25 | $148.4M | $277.0M | ||
| Q2 25 | $146.6M | $263.6M | ||
| Q1 25 | $141.4M | $230.5M | ||
| Q4 24 | $141.8M | $193.6M | ||
| Q3 24 | $128.7M | $227.9M | ||
| Q2 24 | $122.7M | $226.2M | ||
| Q1 24 | $98.5M | $210.9M |
净利润CPRXCSW
| Q4 25 | $52.7M | $10.3M | ||
| Q3 25 | $52.8M | $40.7M | ||
| Q2 25 | $52.1M | $40.9M | ||
| Q1 25 | $56.7M | $35.1M | ||
| Q4 24 | $55.9M | $26.9M | ||
| Q3 24 | $43.9M | $36.1M | ||
| Q2 24 | $40.8M | $38.6M | ||
| Q1 24 | $23.3M | $31.8M |
毛利率CPRXCSW
| Q4 25 | 82.9% | 39.7% | ||
| Q3 25 | 84.7% | 43.0% | ||
| Q2 25 | 85.9% | 43.8% | ||
| Q1 25 | 87.3% | 44.2% | ||
| Q4 24 | 84.7% | 41.4% | ||
| Q3 24 | 85.0% | 45.6% | ||
| Q2 24 | 87.4% | 47.5% | ||
| Q1 24 | 87.3% | 44.4% |
营业利润率CPRXCSW
| Q4 25 | 40.5% | 7.4% | ||
| Q3 25 | 44.7% | 20.5% | ||
| Q2 25 | 45.2% | 20.8% | ||
| Q1 25 | 44.8% | 19.5% | ||
| Q4 24 | 44.3% | 15.3% | ||
| Q3 24 | 39.6% | 22.6% | ||
| Q2 24 | 44.2% | 24.3% | ||
| Q1 24 | 27.5% | 21.0% |
净利率CPRXCSW
| Q4 25 | 34.5% | 4.4% | ||
| Q3 25 | 35.6% | 14.7% | ||
| Q2 25 | 35.6% | 15.5% | ||
| Q1 25 | 40.1% | 15.2% | ||
| Q4 24 | 39.4% | 13.9% | ||
| Q3 24 | 34.1% | 15.8% | ||
| Q2 24 | 33.2% | 17.1% | ||
| Q1 24 | 23.6% | 15.1% |
每股收益（稀释后）CPRXCSW
| Q4 25 | $0.40 | $0.62 | ||
| Q3 25 | $0.42 | $2.41 | ||
| Q2 25 | $0.41 | $2.43 | ||
| Q1 25 | $0.45 | $2.05 | ||
| Q4 24 | $0.44 | $1.60 | ||
| Q3 24 | $0.35 | $2.26 | ||
| Q2 24 | $0.33 | $2.47 | ||
| Q1 24 | $0.19 | $2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $40.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $1.1B |
| 总资产 | $1.1B | $2.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRXCSW
| Q4 25 | $709.2M | $40.2M | ||
| Q3 25 | $689.9M | $31.5M | ||
| Q2 25 | $652.8M | $38.0M | ||
| Q1 25 | $580.7M | $225.8M | ||
| Q4 24 | $517.6M | $213.8M | ||
| Q3 24 | $442.3M | $273.2M | ||
| Q2 24 | $375.7M | $18.9M | ||
| Q1 24 | $310.4M | $22.2M |
总债务CPRXCSW
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $800.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $166.0M |
股东权益CPRXCSW
| Q4 25 | $954.3M | $1.1B | ||
| Q3 25 | $920.2M | $1.1B | ||
| Q2 25 | $856.0M | $1.1B | ||
| Q1 25 | $794.3M | $1.1B | ||
| Q4 24 | $727.6M | $1.0B | ||
| Q3 24 | $660.9M | $1.0B | ||
| Q2 24 | $608.7M | $650.2M | ||
| Q1 24 | $561.4M | $615.7M |
总资产CPRXCSW
| Q4 25 | $1.1B | $2.3B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $971.9M | $1.5B | ||
| Q1 25 | $908.9M | $1.4B | ||
| Q4 24 | $851.4M | $1.4B | ||
| Q3 24 | $772.0M | $1.4B | ||
| Q2 24 | $706.4M | $1.1B | ||
| Q1 24 | $646.7M | $1.0B |
负债/权益比CPRXCSW
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $28.9M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $22.7M |
| 自由现金流率自由现金流/营收 | 29.4% | 9.8% |
| 资本支出强度资本支出/营收 | 0.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.85× | 2.81× |
| 过去12个月自由现金流最近4个季度 | — | $162.0M |
8季度趋势，按日历期对齐
经营现金流CPRXCSW
| Q4 25 | $44.9M | $28.9M | ||
| Q3 25 | $32.4M | $61.8M | ||
| Q2 25 | $71.3M | $60.6M | ||
| Q1 25 | $60.0M | $27.3M | ||
| Q4 24 | $70.9M | $11.6M | ||
| Q3 24 | $72.9M | $66.8M | ||
| Q2 24 | $64.1M | $62.7M | ||
| Q1 24 | $31.9M | $22.4M |
自由现金流CPRXCSW
| Q4 25 | $44.9M | $22.7M | ||
| Q3 25 | — | $58.7M | ||
| Q2 25 | $71.3M | $57.7M | ||
| Q1 25 | — | $22.8M | ||
| Q4 24 | $70.8M | $8.5M | ||
| Q3 24 | $72.6M | $61.3M | ||
| Q2 24 | $64.1M | $59.6M | ||
| Q1 24 | $31.7M | $17.5M |
自由现金流率CPRXCSW
| Q4 25 | 29.4% | 9.8% | ||
| Q3 25 | — | 21.2% | ||
| Q2 25 | 48.6% | 21.9% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | 49.9% | 4.4% | ||
| Q3 24 | 56.4% | 26.9% | ||
| Q2 24 | 52.3% | 26.3% | ||
| Q1 24 | 32.2% | 8.3% |
资本支出强度CPRXCSW
| Q4 25 | 0.0% | 2.6% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 2.0% | ||
| Q4 24 | 0.1% | 1.6% | ||
| Q3 24 | 0.2% | 2.4% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.2% | 2.3% |
现金转化率CPRXCSW
| Q4 25 | 0.85× | 2.81× | ||
| Q3 25 | 0.61× | 1.52× | ||
| Q2 25 | 1.37× | 1.48× | ||
| Q1 25 | 1.06× | 0.78× | ||
| Q4 24 | 1.27× | 0.43× | ||
| Q3 24 | 1.66× | 1.85× | ||
| Q2 24 | 1.57× | 1.62× | ||
| Q1 24 | 1.37× | 0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
